The Centers for Medicare & Medicaid Services (CMS) has launched a new dementia care management program called GUIDE (Guiding an Improved Dementia Experience). This program is designed to improve the quality of care and support for people living with dementia and their caregivers. Isaac Health is a proud participant in the GUIDE Model right from …
CMS Launches New Dementia Care Management Program Read More »
On July 17th, researchers from the TRAILBLAZER-ALZ2 randomized control trial of Donanemab shared the results of their study in parallel to the full publication of their findings. These results represent another remarkable development in Alzheimer’s research. This potential new treatment is showing significant capability in slowing the progression of Alzheimer’s disease, particularly in its early …
New Drug Donanemab Shows Promise: Advancements in Early Alzheimer’s Treatment Read More »
Introduction: The recent full approval of Lecanemab (Leqembi) by the FDA has ushered in a new era in the treatment of Alzheimer’s disease. As the first disease-modifying treatment to receive such approval, Leqembi offers hope to patients with early-stage Alzheimer’s. However, its adoption poses cost implications for payers and risk-bearing health systems. In a newly …
July 6th, 2023, marks a significant milestone in the battle against early Alzheimer’s disease dementia as a groundbreaking new drug, Lecanemab (Leqembi), received full FDA approval. This medication brings hope to individuals grappling with the symptoms and progression of this devastating condition. Isaac Health, at the forefront of innovative healthcare solutions, proudly positions itself as …
In recent news, Senate Minority Leader Mitch McConnell suffered a concussion after a fall. While his condition has not been fully disclosed, the incident highlights the seriousness of concussions, particularly mild traumatic brain injury (TBI). As he recovers from the concussion, many people are curious about this common but often misunderstood injury. As a behavioral …
